Zydus Cadila starts human trials of vaccine

AHMEDABAD: Pharmaceutical major Zydus Cadila has begun human clinical trials of its Covid-19 vaccine candidate called ZyCov-D with the first human dosing on Wednesday.
“The adaptive phase I & II human clinical trials of its plasmid DNA vaccine has commenced on Wednesday with the first human dosing. The adaptive phase I & II dose escalation study will assess the safety, tolerability and immunogenicity of the vaccine,” the firm said in a regulatory filing with the stock exchanges. According to Zydus Cadila, human dosing of the vaccine marks a milestone since the launching of the accelerated vaccine development programme for Covid-19 in February. “We look forward to gathering important data on ZyCoV-D in the months ahead,” said Pankaj Patel, chairman, Zydus Cadila. In the trials, the firm will be enrolling over 1,000 subjects across multiple clinical study sites in India.